Good MorningEquities markets began the day in the green on Thursday but reversed course later. The combined impact of rising oil prices and hawkish Fed-Speak sapped bullish sentiment and drove the S&P 500 down more than 1.0%. Oil prices climbed 2.5% despite easing sanctions on Venezuela. The news is good, but it will be years before Venezuela's oil infrastructure can support large-scale production. WTI has confirmed support at a key level and will likely move higher and underpin inflation.
In other news, Fed chief Jerome Powell says inflation is still too high. In his view, economic growth may have to slow for inflation to hit the 2% target, meaning high rates will be here indefinitely. The risk now is that oil prices will keep the Fed on the brakes, leading to another interest rate hike. In this scenario, more banks fail, and economic slowing could result in a full-blown recession. As it is, the US is only expected to grow by 1.5%, which is far less than the pace of inflation. Featured: Industry Seeing 2,162% Gains (*** LIMITED TIME *** Noram Lithium Corp) 
|
Markets | | |
Today's market is not the one you inherited many years ago; this is entirely different. With giants like BlackRock (NYSE: BLK) and The Goldman Sachs Group (NYSE: GS) guiding their own ships toward a mix of yield and liquidity and away from what seems to be overvalued stocks, you, too, can adjust a... Read the Full Story |
|
From Our PartnersBiden's not holding back...He's warned you that he plans to raise: Income taxes, death taxes, capital gains taxes & corporate taxes. Some or all of which WILL affect you or your family in one way or another…
But it's not too late…yet.
Thousands of Americans are getting their FREE IRS LOOPHOLE KIT to discover the secret to protecting your retirement savings from Biden, and inflation... | | CLICK HERE to request a FREE Copy of the Guide To IRS Loopholes For Your IRA/401(k) |
|
Markets | | |
Shares of Adobe Inc. (NASDAQ: ADBE) are forming a flat base with a 13% correction beneath a September 8 high of $570.24.
While many stocks have tumbled as AI optimism is taking a breather, Adobe has held up. The S&P 500 component is outperforming the S&P 500 by a wide margin on both... Read the Full Story |
|
Stocks | | |
The post-pandemic revenge travel boom may be winding down, at least depending on which company you ask.
Revenge travel refers to the boom that occurred as Covid restrictions eased and people rebooked canceled travel plans and took advantage of their freedom to move around again.
Shar... Read the Full Story |
|
From Our PartnersMaking profits in the stock market depends on making your entry at the right time. The time is NOW to get into A.I. Artificial Intelligence is turning into one of the most popular trends this year, and it has only just begun.
(**By clicking the link you are subscribing to the The Wealth Creation Investing Newsletter and may receive up to 2 additional free bonus subscriptions. Unsubscribing is easy. Full disclosures found here)
| | Go HERE to Reveal Which Stock These Are |
|
Stocks | | |
Since October 5, gold prices have been doing what they tend to do: Rise amid economic and geopolitical uncertainties. That’s why so many investors consider gold either a safe haven or a hedge against falling stock prices.
Gold miners Alamos Gold Inc. (NYSE: AGI) and Gold Fields Limited (NYS... Read the Full Story |
|
Stocks | | | Wall Street racked up more losses Friday to close out its worst week in a month.The S&P 500 fell 1.3% for a fourth straight drop. The Dow Jones Industrial Average sank 286 points, or 0.9%, and the Nasdaq composite tumbled 1.5%.The stock market has been struggling under the weight of the bond mar... Read the Full Story |
|
From Our PartnersInvestors are lining up for gains in the New Uranium Bull Market. One tiny uranium company - currently trading undiscovered by Wall Street around US$0.40 per share - controls one of the largest land positions in the hotbed of global uranium production. Best of all, the vast majority of the firm's projects are being funded by MUCH LARGER companies. | | Do not miss this profit opportunity. |
|
Markets | | | CSX reported a 24% drop in the railroad's third-quarter profit Thursday as it hauled 2% less freight, but the CEO said customers are noticing that its trains are running more smoothly.The Jacksonville, Florida-based railroad said it earned $846 million, or 42 cents per share, in the quarter. That's ... Read the Full Story |
|
Markets | | | Federal Reserve Chair Jerome Powell said Thursday that inflation remains too high and that bringing it down to the Fed's target level will likely require a slower-growing economy and job market.Powell noted that inflation has cooled significantly from a year ago. But he cautioned that the economy is... Read the Full Story |
|
Markets | | | Union Pacific's third-quarter profit fell 19% as the railroad hauled about 3% fewer shipments and costs remained high, but the average speed of its trains improved 5% as new CEO Jim Vena began to tweak the operations Read the Full Story |
|
Markets | | | The Justice Department has secured a $9 million settlement with Ameris Bank over allegations it avoided underwriting mortgages in predominately Black and Latino communities in Jacksonville, Florida, and discouraged people there from getting home loans Read the Full Story |
|
Markets | | |
Netflix, Inc. (NASDAQ: NFLX) stock shot up more than 16% in midday trading the day after it reported blockbuster earnings. But after rocketing past its 200-day and 50-day simple moving averages, is there still room for investors to get involved with NFLX stock?
The streaming giant added nea... Read the Full Story |
|
Friday's Early Bird Stock Of The Day Cerevel Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, develops various therapies for neuroscience diseases in the United States. It is developing Emraclidine, a positive allosteric modulator (PAM) that is in phase 1b clinical trials for the treatment of schizophrenia; and Darigabat, a PAM, which is in Phase 2 proof-of-concept trial in patients with drug-resistant focal onset seizures or focal epilepsy, as well as in phase 1 trial to treat panic symptoms model. The company's products also comprise Tavapadon, a selective dopamine D1/D5 partial agonist that is in phase 3 clinical trial for the treatment of early- and late-stage Parkinson's disease; CVL-871, a selective dopamine D1/D5 partial agonist, which is in Phase 2a clinical trial to treat dementia-related apathy; and CVL-354, a selective kappa-opioid receptor antagonist to treat major depressive disorder and substance use disorder. It is also involved in the development of an M4 agonist program for the treatment of psychosis and related indications; and PDE4 inhibitor for the treatment of psychiatric, neuroinflammatory, and other disorders. Cerevel Therapeutics Holdings, Inc. was founded in 2018 and is headquartered in Cambridge, Massachusetts. | | View Today's Stock Pick |
|
